Furiex Pharmaceuticals Inc (FURX) Financial Statements (2024 and earlier)

Company Profile

Business Address 3900 PARAMOUNT PARKWAY
MORRISVILLE, NC 27560
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2014
MRQ
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 29,15325,718
Cash and cash equivalents 29,15325,718
Receivables 8,17811,745
Prepaid expense 415
Prepaid expense and other current assets320
Total current assets: 37,74637,783
Noncurrent Assets
Property, plant and equipment 87118
Intangible assets, net (including goodwill)49,11649,116
Goodwill 49,11649,116
Restricted cash and investments  7,500
Deferred costs 1,493238
Total noncurrent assets: 50,69656,972
TOTAL ASSETS: 88,44294,755
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 12,37416,834
Accounts payable 7,0726,604
Accrued liabilities 5,30210,230
Debt 10,0805,405
Due to related parties 500 
Total current liabilities: 22,95422,239
Noncurrent Liabilities
Long-term debt and lease obligation 31,92034,595
Long-term debt, excluding current maturities 31,92034,595
Liabilities, other than long-term debt 15,127104
Deferred tax liabilities, net  (220)
Due to related parties 14,500 
Other liabilities 627324
Other undisclosed noncurrent liabilities  220
Total noncurrent liabilities: 47,04734,919
Total liabilities: 70,00157,158
Equity
Equity, attributable to parent 18,44137,597
Common stock 1010
Additional paid in capital 175,094164,577
Accumulated deficit (156,663)(126,990)
Total equity: 18,44137,597
TOTAL LIABILITIES AND EQUITY: 88,44294,755

Income Statement (P&L) ($ in thousands)

3/31/2014
TTM
12/31/2013
12/31/2012
Revenues
(Revenue, Net)
 70,99940,508
Gross profit: 70,99940,508
Operating expenses (95,437)(80,852)
Operating loss: (24,438)(40,344)
Nonoperating income
(Other Nonoperating income)
 931
Interest and debt expense (4,980)(2,508)
Loss from continuing operations before income taxes: (29,325)(42,851)
Income tax expense (348)(14)
Loss from continuing operations: (29,673)(42,865)
Loss before gain (loss) on sale of properties: (29,673)(42,865)
Net loss available to common stockholders, diluted: (29,673)(42,865)

Comprehensive Income ($ in thousands)

3/31/2014
TTM
12/31/2013
12/31/2012
Net loss: (29,673)(42,865)
Comprehensive loss, net of tax, attributable to parent: (29,673)(42,865)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: